Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov;85(5):e162-e163.
doi: 10.1016/j.jinf.2022.07.014. Epub 2022 Jul 22.

Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment

Camille Vellas  1 , Nassim Kamar  2 , Jacques Izopet  3
Affiliations
Comment

Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment

Camille Vellas et al. J Infect. 2022 Nov.
No abstract available

Keywords: Cilgavimab; Mutations; Neutralizing monoclonal antibodies; SARS-CoV-2; Sequencing; Tixagevimab.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare no conflict of interest.

Comment in

Comment on

References

    1. Yang M., Li A., Wang Y., Tran C., Zhao S., Ao G. Monoclonal antibody therapy improves severity and mortality of COVID-19 in organ transplant recipients: a meta-analysis. J Infect. 2022 doi: 10.1016/j.jinf.2022.06.027. - DOI - PMC - PubMed
    1. Takashita E., Kinoshita N., Yamayoshi S., Sakai-Tagawa Y., Fujisaki S., Ito M., et al. Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant. N Engl J Med. 2022;386(10):995–998. doi: 10.1056/NEJMc2119407. - DOI - PMC - PubMed
    1. Vellas C., Trémeaux P., Del Bello A., Latour J., Jeanne N., Ranger N., et al. Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab. Clin Microbiol Infect. 2022;(22) doi: 10.1016/j.cmi.2022.05.002. S1198-743X00258-0. - DOI - PMC - PubMed
    1. Montgomery H., Hobbs F.D.R., Padilla F., Arbetter D., Templeton A., Seegobin S., et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022;S2213-2600(22):00180–00181. doi: 10.1016/S2213-2600(22)00180-1. - DOI - PMC - PubMed
    1. Vellas C., Del Bello A., Debard A., Steinmeyer Z., Tribaudeau L., Ranger N., et al. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies. Clin Microbiol Infect. 2022;28(1) doi: 10.1016/j.cmi.2021.09.008. 139.e5-139.e8. - DOI - PMC - PubMed

Supplementary concepts

LinkOut - more resources